Results 81 to 90 of about 4,513 (159)

Preparation and Characterization of Aprepitant Solid Dispersion with HPMCAS-LF [PDF]

open access: gold, 2022
Jinwen Liu   +5 more
openalex   +1 more source

Anti-Cancer Effect of Aprepitant on Nb4 Leukemic Cells

open access: yesMajallah-i Dānishgāh-i ̒Ulūm-i Pizishkī-i Bābul, 2017
BACKGROUND AND OBJECTIVE: Genetic studies have demonstrated that the neurokini-1 Receptor (NK1R (is frequently involved in the pathogenesis of wide assortment of human malignancies, including acute promyelocytic leukemia (APL).
E Razani   +4 more
doaj  

Safety and efficacy of aprepitant as mono and combination therapy for the prevention of emetogenic chemotherapy-induced nausea and vomiting: post-marketing surveillance in China [PDF]

open access: diamond, 2020
Yunpeng Yang   +27 more
openalex   +1 more source

Efficacy of aprepitant for prevention of postoperative nausea and vomiting. Systematic review and meta-analysis of randomized clinical trials

open access: yesIatreia, 2014
Objective: To evaluate the efficacy of aprepitant compared with other antiemetics for the prevention of postoperative nausea and vomiting in adults who underwent general anesthesia.
Berrío Valencia, Marta Inés   +1 more
doaj  

Efficacy of Aprepitant in Patients with Advanced or Recurrent Lung Cancer Receiving Moderately Emetogenic Chemotherapy

open access: gold, 2012
Junji Uchino   +11 more
openalex   +2 more sources

Aprepitant, Granisetron, and Dexamethasone for Prevention of Chemotherapy-Induced Nausea and Vomiting After High-Dose Melphalan in Autologous Transplantation for Multiple Myeloma: Results of a Randomized, Placebo-Controlled Phase III Trial [PDF]

open access: bronze, 2014
Thomas Schmitt   +11 more
openalex   +1 more source

Aprepitant use during chemotherapy and association with survival in women with early breast cancer. [PDF]

open access: yesJ Natl Cancer Inst
Botteri E   +10 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy